LY-02. Treatment strategy of patients with relapsed and refractory aggressive B-cell non-Hodgkin lymphoma

Cellular Therapy and Transplantation

article

Liudmila V. Fedorova¹  Olesya G. Smykova¹  Andrey M. Chekalov¹  Marina O. Popova¹  Vladislav V. Markelov¹  Elena V. Kondakova¹  Ivan S. Moiseev¹  Kirill V. Lepik¹  Natalia B. Mikhailova¹  Alexander D. Kulagin¹ 

[1] RM Gorbacheva Research Institute, Pavlov University

关键词: Non-Hodgkin lymphoma;    immunotherapy;    targeted therapy;    glofitamab;    polatuzumab vedotin;    adverse events.;   

DOI  :  10.18620/ctt-1866-8836-2022-11-3-1-132

学科分类：肿瘤学

来源: Universitaetsklinikum Hamburg - Eppendorf / University Medical Center Hamburg - Eppendorf

【 摘 要 】

Up to 40-50% of patients with aggressive B-cell non-Hodgkin lymphoma (B-NHL) remain refractory to treatment, or develop relapse (r/r) after 1-2 lines of therapy. The prognosis of this patient’s group remains unfavorable. However, the emergence of new methods of targeted drug and immunotherapy (polatuzumab vedotin, Pola; glofitamab) may improve both progression-free survival (PFS) and overall survival (OS) rates in the patients with r/r B-NHL. The aim of our study was to suggest the treatment strategy for this population of patients, as well as to determine place for allogeneic hematopoietic stem cell transplantation (allo-HSCT).

【 授权许可】

CC BY